News
ACOR
0.9500
+6.42%
0.0573
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 01/23 21:31
BRIEF-Acorda Therapeutics - On Dec 31, 2022, Entered New Msa With Catalent Massachusetts Llc, Terminated Prior Manufacturing Services Agreement, Dated Feb 10, 2021
Reuters · 01/05 22:21
Acorda strikes new global supply deal with Catalent for its inhalation powder Inbrija
Seeking Alpha · 01/05 22:14
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/05 21:30
Acorda Therapeutics Announces New Agreement With Catalent For Long-Term Global Supply Of INBRIJA
Benzinga · 01/05 21:20
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
Benzinga · 12/22/2022 13:04
Acorda Therapeutics Lowers Guidance to Correct Overstated Adjusted EBITDA, Cash Flow
Acorda Therapeutics Lowers Guidance to Correct Overstated Adjusted EBITDA, Cash Flow
MT Newswires · 12/22/2022 12:56
Acorda Therapeutics Gets Nasdaq Notice for Potential Delisting; Plans to Request Hearing
Acorda Therapeutics Gets Nasdaq Notice for Potential Delisting; Plans to Request Hearing
MT Newswires · 12/21/2022 04:41
Acorda Therapeutics Receives Nasdaq Listing Determination Letter, Plans To Request Hearing
Benzinga · 12/20/2022 22:30
Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
PEARL RIVER, N.Y., December 05, 2022--Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash
Business Wire · 12/05/2022 12:01
How Is The Market Feeling About Acorda Therapeutics?
Benzinga · 11/09/2022 20:06
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/08/2022 10:00
BRIEF-Acorda Therapeutics Announces Adjournment Of Special Meeting Of Stockholders
Reuters · 11/04/2022 14:54
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
PEARL RIVER, N.Y., November 04, 2022--Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
Business Wire · 11/04/2022 13:25
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/02/2022 12:20
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Benzinga · 11/02/2022 09:07
BRIEF-Acorda Therapeutics Reports Third Quarter 2022 Financial Results
Reuters · 11/01/2022 21:17
Acorda Therapeutics Q3 EPS $(0.55) Up From $(1.43) YoY, Sales $33.51M Miss $36.97M Estimate
Benzinga · 11/01/2022 20:37
Acorda Therapeutics GAAP EPS of -$0.57, revenue of $33.51M
Seekingalpha · 11/01/2022 20:14
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/01/2022 18:10
More
Webull provides a variety of real-time ACOR stock news. You can receive the latest news about Acorda Thrpeutcs through multiple platforms. This information may help you make smarter investment decisions.
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The Company uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). INBRIJA is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. INBRIJA utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.